Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with GuadecitabineCasey L. O’Connell, Kirsten Grønbæk, Maria R. Baer et al.|Clinical Cancer Research|2022Cited by 27
Circulating YKL-40 in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV) treated with the Novel Histone Deacetylase Inhibitor VorinostatChristen Lykkegaard Andersen, Hans Carl Hasselbalch, Sonja Zweegman et al.|University of Southern Denmark Research Portal (University of Southern Denmark)|2013Cited by 0